{ "items": [ "\n\n
\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nWe define how the immune system functions in the intestine to promote health. We uncover the immune pathogenesis of intestinal diseases such as inflammatory bowel disease to develop better ways to treat these disorders.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nOur group is interested in developing novel immunotherapeutic approaches for leukaemia. Clinical approaches currently used include allogeneic haematopoietic stem cell transplantation, chimeric antigen receptor T cell therapy and immune checkpoint inhibitors. While each of these approaches can be successful, they also fail in many patients as a result of tumour adaptations or diminished function of immune cells. Enhanced immunity can also lead to immune-related adverse events due to on- or off-target effects. We are exploring the mechanisms that underpin these failures and using this information to devise new strategies that can be translated into early phase clinical trials.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nFounded in 2015, we are investigating the link between human fetal haematopoiesis and the origin and biology of childhood leukaemia. In particular, we are interested in the pathogenesis of infant leukaemia, which is a refractory disease that invariably originates in utero.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nThe Haematopoietic Stem Cell Biology (HSCB) Laboratory is focused on understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. Our overarching aim is to improve the management of myeloproliferative neoplasms and related conditions through better monitoring and therapeutic targeting of malignant stem cell populations.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nResearch in the Jacobsen group is focused at unravelling normal and malignant hematopoietic stem and progenitor cell biology at the single cell level.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nWe are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \n\ufeffWe study endogenous DNA damage caused by metabolites and their impact on the function of vertebrate stem cells and the ageing process
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Centre for Computational Biology\n \n \n\n \n\n\n
\n \n \n \nWe are a computational biology research group using genomic and functional genomic data to study transcriptional regulation in neuroscience.
\n \n\n \n \nWe focus on systems level \u201cbig picture\u201d approaches to understand gene regulation and build gene regulatory networks during development and disease in zebrafish, chick, lamprey and human models.
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Centre for Computational Biology\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nUsing genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nHematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \nImmune mechanisms of lung injury, regeneration and fibrosis; identifying new therapeutic targets, and improved treatment for idiopathic pulmonary fibrosis and sarcoidosis. \r\nSee our Spotlight video - https://youtu.be/Dj0uNQgA1Fs
\n \n\n \n \n\n \n\n \n \n \n \n MRC TIDU\n \n \n\n \n\n\n
\n \n \n \n\n \n \nWe work to translate an understanding of the molecular mechanisms of disease at the neuromuscular synapse into treatments. Our work led us to be commissioned to provide a National Advisory and Diagnostic Service for congenital myasthenic syndromes.
\n \n\n \n \nOvarian cancer is one of the most lethal gynaecological malignancies predominantly because of late presentation and chemotherapy resistance. Recent advances in single cell RNA sequencing and DNA sequencing have made it possible to obtain unprecedented insights into tumour biology. Our lab has developed sequencing strategies and analysis algorithms to accelerate the mechanistic understanding of ovarian cancer initiation, progression and chemotherapy resistance. The use of these technologies and our access to patients recruited in clinical research studies provide exciting opportunities for addressing key questions in ovarian cancer such as a) understanding the cell of origin of ovarian cancer, b) characterising the tumour initiating cells in minimal residual disease and c) understanding T cell immune responses against ovarian cancer initiation and progression.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nWe aim to understand the fundamental biological processes underlying normal and malignant haematopoiesis and translate this to improve patient outcomes through new rational therapies.
\n \n\n \n \n\n \n\n \n \n \n \n MRC MHU\n \n \n\n \n\n\n
\n \n \n \nAberrant epigenetic changes are a driving force in many human cancers. The focus of our lab is centred on understanding how epigenetics impacts gene regulation so that this information can potentially be used to develop new therapeutic strategies.
\n \n\n \n \nWe use state-of-the-art laboratory and computational approaches to understand how mammalian genes are switched on and off during development and differentiation and how this goes awry in human genetic diseases.
\n \n\n \n \n